Company news
Benitec Biopharma Inc. (NASDAQ:BNTC) news
Every Benitec Biopharma Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
September 14, 2026
Unleash Your Ultimate Kaiju! Godziburst and Godzilla Scramble Figures Available for Pre-Order Starting June 25
June 25, 2026
Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update
May 14, 2026
Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting
April 28, 2026
Benitec Biopharma to Host Industry Forum Breakfast Event at the 2026 Muscular Dystrophy Association Clinical and Scientific Conference on March 10, 2026, Highlighting Continued Progress for BB-301, the Only Clinical-Stage Therapeutic in Development fo...
March 10, 2026
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
March 9, 2026
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
February 23, 2026
Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update
February 12, 2026
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
January 11, 2026
Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update
November 14, 2025
Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering
November 6, 2025
Benitec Biopharma Inc. Announces Proposed Public Offering
November 5, 2025
Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
November 3, 2025
Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
November 3, 2025
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
November 2, 2025
Benitec Biopharma : Annual Report for Fiscal Year Ending June 30, 2025 (Form 10-K)
September 23, 2025
Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
September 22, 2025
Benitec Biopharma Provides Operational Updates
July 9, 2025
Benitec Biopharma Releases Third Quarter 2025 Financial Results
May 14, 2025
Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering
March 25, 2025
Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
March 19, 2025
Benitec Biopharma to Participate in Upcoming Conferences in March
February 26, 2025
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
February 14, 2025
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update
February 14, 2025
Benitec Biopharma to Participate in Upcoming Conferences in January and February
January 27, 2025
Benitec Biopharma to Participate in Upcoming Investor Conferences in December
November 26, 2024
Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update
November 14, 2024
Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference
November 4, 2024
Benitec Biopharma Announces Updated Investor Webcast Information
October 14, 2024
Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society
October 12, 2024
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
September 26, 2024
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
September 18, 2024
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
September 17, 2024
Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study
July 15, 2024
Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors
July 1, 2024
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
May 13, 2024
Benitec Biopharma to Participate in the Citizens JMP Life Science Conference
May 1, 2024
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
April 18, 2024
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
April 18, 2024
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
April 9, 2024
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
February 13, 2024
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
November 30, 2023
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
November 17, 2023
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
November 13, 2023
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
September 21, 2023
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
August 11, 2023
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
August 8, 2023
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
July 25, 2023
Benitec Biopharma Receives FDA Clearance of the IND for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
June 26, 2023
Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update
May 15, 2023